Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 12/20 | 0.48 |
| ▸ | CDK2 | P24941 | 12/20 | 0.48 |
| ▸ | CDK4 | P11802 | 6/20 | 0.48 |
| ▸ | CDK1 | P06493 | 5/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 11/20 | 0.46 |
| ▸ | CCND1 | P24385 | 5/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2175131 | 0.78 | RAB9A (0.60) | CCNE1CDK2CDK4CDK1LMNA | |
| SCHEMBL1749806 | 0.77 | SMN1; SMN2 (0.59) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL966406 | 0.77 | ALOX15 (0.53) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL4522999 | 0.77 | CCNE1 (0.59) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL1763394 | 0.77 | CCNE1 (0.48) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL13158536 | 0.77 | CCNE1 (0.48) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL2371104 | 0.77 | FFAR2 (0.52) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL5216438 | 0.77 | CCNE1 (0.48) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL4963441 | 0.77 | LMNA (0.53) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL27819346 | 0.76 | CA1 (0.47) | CCNE1CDK2CDK4CDK1CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063048-B2 | Acetylenyl-pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| CN-101180299-B | Ethynyl-pyrazolopyrimidine derivatives as MGLUR2 antagonists | HOFFMANN LA ROCHE | 2010-12-15 | — | — | CN | disclosed |
| US-20100210642-A1 | ACETYLENYL-PYRAZOLO-PYRIMIDINE DERIVATIVES | GATTI MCARTHUR SILVIA | 2010-08-19 | — | — | US | disclosed |
| US-7718661-B2 | Acetylenyl-pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| EP-1863818-B1 | ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-03-10 | — | — | EP | disclosed |
| US-20080300250-A1 | ACETYLENYL-PYRAZOLO-PYRIMIDINE DERIVATIVES | GATTI MCARTHUR SILVIA | 2008-12-04 | — | — | US | disclosed |
| US-7446113-B2 | Acetylenyl-pyrazolo-pyrimidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-04 | — | — | US | disclosed |
| CN-101180299-A | Ethynyl-pyrazolopyrimidine derivatives as MGLUR2 antagonists | HOFFMANN LA ROCHE (CH) | 2008-05-14 | — | — | CN | disclosed |
| EP-1863818-A1 | ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| US-20070167460-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | MCARTHUR SILVIA G | 2007-07-19 | — | — | US | disclosed |
| US-7238808-B2 | Acetylenyl-pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060217387-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-09-28 | — | — | US | disclosed |
| WO-2006099972-A1 | ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| EP-1087951-B9 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1087951-B1 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2005-02-09 | — | — | EP | disclosed |
| US-6720347-B2 | SUCH AS ETHYL-3-((E)-2-ACETAMIDO-THIAZOL-5-YL)-ACRYLATE FOR TREATMENT OF CANCER, PROLIFERATIVE DISEASES, INFLAMMATION, AND ARTHRITIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-13 | — | — | US | disclosed |
| US-20020165259-A1 | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases | RAWLINS DAVID B (US) | 2002-11-07 | — | — | US | disclosed |
| US-6407124-B1 | ANTICARCINOGENIC, ANTIPROLIFERATIVE, ANTIINFLAMMATORY, AND ANTIARTHRITIC AGENTS; ALZHEIMER*S DISEASE AND CARDIOVASCULAR DISORDER TREATMENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210642-A1 | ACETYLENYL-PYRAZOLO-PYRIMIDINE DERIVATIVES | NAT1, TPMT, ACAT1 | CCNE1 41/4885CDK2 11/4885CDK4 370/4885 |
| US-20080300250-A1 | ACETYLENYL-PYRAZOLO-PYRIMIDINE DERIVATIVES | NAT1, TPMT, ACAT1 | CCNE1 41/4885CDK2 11/4885CDK4 370/4885 |
| US-20060217387-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | NAT1, TPMT, ACAT1 | CCNE1 41/4885CDK2 11/4885CDK4 370/4885 |
| US-20070167460-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | NAT1, ADORA2B, TPMT | CCNE1 59/4885CDK2 11/4885CDK4 503/4885 |
| US-20020165259-A1 | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases | CCNK, CDK2, CCNL2 | CCNE1 12/4885CDK2 2/4885CDK4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.